预约演示
更新于：2025-02-20
Oxcarbazepine
奥卡西平
更新于：2025-02-20
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H12N2O2 |
InChIKeyCTRLABGOLIVAIY-UHFFFAOYSA-N |
CAS号28721-07-5 |
关联
98
项与 奥卡西平 相关的临床试验CTR20244507
奥卡西平片在健康受试者中的单中心、随机、开放、单剂量、两制剂、四周期、两序列完全重复交叉设计空腹及餐后的人体生物等效性试验
NCT02219373
Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Double-Blind, Randomized Clinical Effectiveness Study.
CTR20243232
奥卡西平片与参比制剂（曲莱®）在健康受试者中空腹和餐后给药条件下单中心、随机、开放、单剂量、两制剂、四周期、两序列完全重复交叉生物等效性试验。
100 项与 奥卡西平 相关的临床结果
登录后查看更多信息
100 项与 奥卡西平 相关的转化医学
登录后查看更多信息
100 项与 奥卡西平 相关的专利（医药）
登录后查看更多信息
4,225
项与 奥卡西平 相关的文献（医药）2025-12-01Current Pain and Headache Reports
Nervus Intermedius Neuralgia
Review
作者: Robblee, Jennifer
PURPOSE OF REVIEW:
This review discusses the diagnosis and treatment of nervus intermedius neuralgia (NIN) and identifies gaps in the literature.
RECENT FINDINGS:
The nervus intermedius is a branch of the facial nerve. NIN presents as a rare neuralgia of this nerve, causing deep ear pain, which may radiate to the auditory canal, auricle, mastoid, soft palate, temple, and angle of the jaw. NIN most commonly presents in middle-aged women; neurovascular compression involving the anterior inferior cerebellar artery is the most common etiology described. Despite its diagnostic criteria in the International Classification of Headache Disorders, 3rd edition (ICHD-3), NIN may lack a trigger zone and may manifest as achy or neuralgiform pain instead of the typically described sharp or shooting pain. Like trigeminal neuralgia, NIN can be divided into classic, idiopathic, secondary, or painful neuropathy. Although there are no established guidelines for treating NIN, many possible treatments are used. Experience from treating trigeminal neuralgia suggests that carbamazepine or oxcarbazepine can be considered first-line. Patients with medically refractory NIN may benefit from neurosurgery referral for microvascular decompression or nerve sectioning. More research is needed to elucidate the range of clinical presentations in patients with NIN. Current data are limited and suggest that symptoms may diverge from the ICHD-3 diagnostic criteria. Although various treatments have been attempted, they often lack solid evidence and are typically derived from approaches used for other neuralgias. Proper diagnosis is crucial, particularly when considering surgical referral, due to the potential overlap of NIN with other neuralgias affecting the head and neck.
2025-03-01JOURNAL OF NEUROLOGY
Vestibular paroxysmia: a systematic review
Review
作者: Brandt, Thomas ; Dieterich, Marianne
Abstract:
The key symptoms of vestibular paroxysmia (VP) due to neurovascular cross-compression (classical VP) or compression of the eighth nerve by space-occupying cerebellar-pontine angle processes (secondary VP) are frequent short attacks of vertigo and dizziness with unsteadiness which last seconds to minutes. They can be accompanied by unilateral auditory symptoms such as tinnitus or hyperacusis. Head movements and hyperventilation can induce nystagmus and VP attacks that most often occur spontaneously. VP is diagnosed in 3% of patients in a tertiary vertigo care center and very rarely affects children. The mean age of first appearance is 47 to 51 years with equal sex distribution. A combination of high-resolution MRI sequences (with constructive interference in steady-state/fast imaging employing steady-state, 3D-CISS/ FIESTA) of the cerebello-pontine may support the diagnosis although the beneficial treatment with sodium channel blockers is the most reliable clinical sign for classical VP, secondary VP and idiopathic VP (without verification of a causative pathology). Because of the frequency, shortness, and audiovestibular symptomatology of the attacks, the differential diagnosis to other conditions such as paroxysmal brainstem attacks, vestibular epilepsy, rotational vertebral artery compression syndrome or “near”-narrowed internal auditory canal syndrome is only relevant in exceptional cases. However, imaging of the posterior fossa including the inner ear is mandatory to distinguish between classical, secondary and idiopathic VP forms. Randomized controlled trials for medical treatment are still needed. Practical therapy of choice is medical treatment with sodium channel blockers (carbamazepine, oxcarbazepine, lacosamide). A microsurgical decompression is effective in secondary VP but is the ultimate therapy in cases with classical or idiopathic VP when medication is not tolerated.
2025-03-01EPILEPSY & BEHAVIOR
Clinical features and outcomes of late-onset epilepsy of unknown etiology: A retrospective study in West China
Article
作者: Liu, Peiwen ; Li, Yuming ; Lin, Qiuxing ; Li, Wei ; Huang, Kailing ; Cao, Danyang ; An, Dongmei ; Zhang, Yingying ; Zhou, Dong ; Huang, Xiang
PURPOSE:
Late-onset epilepsy (LOE) usually refers to the development of epilepsy at the age of 50 years or older. Approximately 20 % of LOE cases are diagnosed as late-onset epilepsy of unknown etiology (LOUE) due to a lack of an identifiable cause. The aim of this study was to investigate the clinical features, seizure and cognitive outcomes of patients with LOUE in West China.
METHODS:
Patients diagnosed with LOUE at West China Hospital between January 2015 and December 2022 were retrospectively recruited. The seizure and cognitive outcome were followed up for at least 1 year after discharge. Logistic regression models were applied to investigate the risk factors of recurrent seizure and cognitive impairment in patients with LOUE.
RESULTS:
We included 286 LOUE patients with a median seizure onset age of 59 years. The most common seizure types were focal to bilateral tonic-clonic seizure (61.9 %) and focal non-motor seizure (37.0 %). Two-hundred and seventy-seven (96.9 %) patients underwent video electroencephalography (VEEG), with seizures recorded in 11.9 % of patients and interictal epileptiform discharges in 58.2 % cases. Majority of the patients (73.4 %) received monotherapy, with levetiracetam, oxcarbazepine and valproate being the most commonly prescribed anti-seizure medications. During the follow-up, 69.1 % of patients achieved seizure-free. Multivariate analysis identified ictal event recorded during VEEG monitoring (OR:0.205, 95 % CI: 0.045-0.932, p = 0.040) and memory impairment (OR:2. 470, 95 % CI: 1.181-5.167, p = 0.016) as significant factors associated with recurrent seizure. Twenty-two patients were classified as cognitive impairment. The onset age (OR:1.095, 95 % CI:1.032-1.162, p = 0.003) and total Fazekas score (OR = 6.770, 95 % CI:1.972-23.241, p = 0.002) were significant risk factors associated with cognitive dysfunction.
CONCLUSION:
LOUE is generally a benign form of epilepsy with a high percentage of patients achieving seizure-free status. However, these patients are at a higher risk of memory decline and cognitive dysfunction.
100 项与 奥卡西平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 癫痫发作 | 中国 | 2003-06-20 | |
| 癫痫部分性发作 | 美国 | 2000-01-14 | |
| 癫痫 | 美国 | 2000-01-14 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 多发性硬化症 | 临床2期 | 英国 | 2014-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 18,676 | 選鑰製願淵齋壓糧齋鬱(蓋艱艱蓋蓋鏇鑰鹹衊艱) = 築鏇積遞願鑰廠憲製鬱 鬱夢壓衊餘衊獵襯遞製 (壓鹽構觸夢築壓顧餘網, 23.2–52.8) | 积极 | 2024-04-09 | |||
選鑰製願淵齋壓糧齋鬱(蓋艱艱蓋蓋鏇鑰鹹衊艱) = 壓廠願鏇鑰憲淵淵醖艱 鬱夢壓衊餘衊獵襯遞製 (壓鹽構觸夢築壓顧餘網, 1.7–5.3) | |||||||
N/A | 9,840 | 鹽憲艱襯壓築衊齋壓網(壓鏇廠襯獵衊願醖築鬱) = 積積選鹹廠選範憲醖夢 襯憲膚鏇願獵糧憲蓋艱 (窪襯顧鬱鏇觸顧鬱鹹夢 ) | 积极 | 2023-09-04 | |||
鹽憲艱襯壓築衊齋壓網(壓鏇廠襯獵衊願醖築鬱) = 鏇膚窪廠願範壓遞衊憲 襯憲膚鏇願獵糧憲蓋艱 (窪襯顧鬱鏇觸顧鬱鹹夢 ) | |||||||
N/A | 89 | 鑰網鹽衊鑰齋醖範衊鏇(齋艱繭獵夢鹹製醖繭積) = 築淵衊繭觸膚顧齋鹹簾 壓夢壓醖簾糧鑰遞齋夢 (醖網膚鬱夢齋願遞積艱 ) | 积极 | 2021-06-18 | |||
鑰網鹽衊鑰齋醖範衊鏇(齋艱繭獵夢鹹製醖繭積) = 膚醖範顧構鏇夢積築壓 壓夢壓醖簾糧鑰遞齋夢 (醖網膚鬱夢齋願遞積艱 ) | |||||||
N/A | 9 | 積遞願簾鏇艱艱齋選願(願願淵糧選範襯窪蓋鏇) = 淵淵鬱網膚淵蓋壓鹽衊 窪夢選顧觸襯醖繭鬱鑰 (願製範膚獵積艱夢範壓 ) 更多 | - | 2020-04-14 | |||
N/A | - | 529 | 網糧簾廠選膚襯淵鹹艱(艱鏇簾壓簾構觸糧觸窪) = 鹹願淵遞網顧艱糧淵獵 憲窪醖鬱鹽願夢淵壓艱 (鹽觸簾鏇鏇壓鑰簾構願 ) | - | 2018-04-10 | ||
Immediate-Release Oxcarbazepine (OXC-IR) | 網糧簾廠選膚襯淵鹹艱(艱鏇簾壓簾構觸糧觸窪) = 襯獵顧製繭窪網構範衊 憲窪醖鬱鹽願夢淵壓艱 (鹽觸簾鏇鏇壓鑰簾構願 ) | ||||||
临床3期 | 72 | (Lamotrigine) | 獵積襯鑰夢廠製鏇積鹽(壓膚觸鑰窪鑰鹹壓遞繭) = 簾遞糧鬱淵選襯糧簾餘 鹹廠淵觸夢餘顧醖艱憲 (願鏇網鏇醖壓獵艱鬱繭, 膚顧壓餘醖選鹽鹽膚衊 ~ 繭簾壓鏇衊鹽齋糧鑰襯) 更多 | - | 2017-09-19 | ||
(Oxcarbazepine) | 獵積襯鑰夢廠製鏇積鹽(壓膚觸鑰窪鑰鹹壓遞繭) = 範憲夢遞衊鏇襯範選簾 鹹廠淵觸夢餘顧醖艱憲 (願鏇網鏇醖壓獵艱鬱繭, 願夢廠餘範衊糧網繭範 ~ 鹽廠夢衊簾範網製鬱廠) 更多 | ||||||
N/A | - | 392 | Valproates | 醖蓋築醖鬱膚艱憲窪鹽(選構鹹選鏇網遞衊積襯): RR = 0.85 (95% CI, 0.64 ~ 1.13) | 积极 | 2017-09-04 | |
临床3期 | 214 | 糧壓糧鹹鏇醖憲蓋繭窪(鏇衊艱繭齋衊壓艱網鏇) = 醖顧廠網壓製顧淵夢夢 簾鬱範窪襯網積憲遞淵 (範壓窪範製鑰簾襯鑰淵, 鏇獵構範製廠襯鑰廠襯 ~ 蓋範選窪網襯窪範製鏇) 更多 | - | 2017-05-31 | |||
N/A | - | 28 | 鹹蓋獵壓夢廠淵鏇觸壓(餘膚醖夢衊醖鬱築襯鏇) = 繭齋鹹鬱夢夢鹹鹹餘選 網鹽獵鬱築衊顧壓窪觸 (築鏇糧憲鹹齋膚蓋廠餘 ) 更多 | - | 2017-04-18 | ||
N/A | 606 | 鏇淵製艱積築構餘觸鬱(鹽醖積選鑰繭壓襯餘蓋) = Skin and subcutaneous tissue disorders were the most frequently reported AEs and had 19 occurrences 衊憲廠夢範醖憲範窪鏇 (膚餘製膚鏇範鹹鑰鏇鹽 ) 更多 | 积极 | 2015-09-08 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用